Clinical Trial Update: Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine with or without pazopanib in refractory soft tissue sarcoma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pazopanib (Pazopanib)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2021-02-09